Key takeaways
Viloxazine (Qelbree) and dextroamphetamine/amphetamine salts (Adderall) are both medications used to treat attention-deficit hyperactivity disorder (ADHD) in children and adults. However, they belong to different medication classes and have distinct characteristics. Viloxazine is a selective norepinephrine reuptake inhibitor (NRI) and is not a controlled substance, meaning it has no risk of abuse or dependence. It is taken once daily and is not considered a first-choice option for ADHD. Adderall, on the other hand, is a stimulant medication and a Schedule II controlled substance, which means it has a high risk for misuse and dependence. It is typically taken multiple times a day and is a first-choice option for ADHD. Viloxazine is only available as a brand-name medication, while Adderall is available in both brand-name and generic forms. Common side effects of viloxazine include sleep problems and headache, while Adderall can cause trouble sleeping and loss of appetite. Both medications can raise blood pressure, but Adderall also increases the risk of serotonin syndrome. Both medications have many drug interactions, so be sure your prescriber and pharmacist have a complete list of your medications.
